AzTrials
AzTrials

Shoulder PainSHOULDERVRNCT06795464

Effectiveness of Immersive Virtual Reality on Biomarkers and Clinical and Clinimetric Variables in Patients With Persistent Shoulder Pain

A study testing Immersive Virtual Reality and Exercise in people with Shoulder Pain, run by Universidad Francisco de Vitoria at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Shoulder pain is one of the primary reasons for seeking physiotherapy care. The high prevalence of rotator cuff-related shoulder pain underscores the need for research into novel treatment approaches that may enhance the clinical outcomes of conventional physiotherapy interventions. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Shoulder Pain
What is being tested?
Immersive Virtual Reality and Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
44 participants
Where
1 siteSpain
Study dates
1 Mar 2025to 28 Apr 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age between 18 and 70 years.
  • Shoulder pain persisting for at least six months.
  • Presence of shoulder pain during movement.
  • Clinical diagnosis of rotator cuff-related shoulder pain.
  • Willingness to participate in the study and signing of informed consent.

Who cannot join

  • Shoulder pain related to cervical spine conditions.
  • Presence of pain in the elbow, wrist, and/or hand.
  • Clinical diagnosis of frozen shoulder.
  • Clinical diagnosis of shoulder instability.
  • Cognitive impairments.
  • Concomitant physiotherapy treatments during the study period.
Show all 11Show fewer
  • History of trauma associated with the onset of shoulder pain.
  • Previous fractures in the affected shoulder.
  • Prior surgeries in the affected shoulder.
  • Use of analgesic or anti-inflammatory medications within 24 hours prior to study participation.
  • Presence of rheumatic or neurological diseases.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Universidad Francisco de Vitoria

    Madrid, Madrid, 28223

Other trials in Spain

About this study

Official title: Effectiveness of Immersive Virtual Reality on Clinical Variables, Clinimetric Measurements, and Biomarkers in Patients With Persistent Shoulder Pain: A Randomized Multicenter Clinical Trial

Shoulder pain is one of the primary reasons for seeking physiotherapy care. The high prevalence of rotator cuff-related shoulder pain underscores the need for research into novel treatment approaches that may enhance the clinical outcomes of conventional physiotherapy interventions.

Immersive Virtual Reality (IVR) has been demonstrated to serve as an effective adjunct for pain management by providing distraction and altering patients' pain perception. Specifically, when used alongside exercise, IVR has been shown to induce hypoalgesia in individuals with chronic low back pain. Additionally, IVR is emerging as a promising tool to enhance motivation and improve adherence to rehabilitation protocols, which is critical for long-term treatment implementation and achieving positive outcomes. These findings suggest that virtual reality may provide an innovative approach to managing pain in patients with rotator cuff-related shoulder pain, improving their pain experience, functionality, and quality of life.

Read more

To date, no study has directly compared the effectiveness of combining IVR with standard physiotherapy treatments versus standard treatments alone on clinical variables, clinimetric measures, and biomarkers in individuals with persistent shoulder pain related to the rotator cuff. Therefore, conducting a randomized multicenter clinical trial on this subject, facilitated by international collaboration among RIU-affiliated universities, could provide a robust foundation for implementing new technologies such as virtual reality in pain management and advancing rehabilitation strategies.

The objective of this project is as follows:

To compare the effectiveness of combining immersive virtual reality with standard physiotherapy treatment versus standard treatment alone on clinical variables, clinimetric measures, and biomarkers in individuals with persistent rotator cuff-related shoulder pain.

Read the detailed description

Shoulder pain represents the third most common cause of musculoskeletal pain and the leading cause of non-traumatic upper limb pain. This condition holds significant musculoskeletal relevance, as up to 66.7% of individuals experience shoulder pain at least once in their lifetime, and symptoms persist beyond 18 months in 50% of cases, impacting daily activities at home and in the workplace. Furthermore, shoulder pain can disrupt sleep patterns and contribute to work-related challenges, such as sick leave, early retirement, or job loss. Persistent shoulder pain also imposes significant socioeconomic costs, estimated at $7 billion in the United States in 2000 and exceeding €1.5 million between 2004 and 2007 in the Canary Islands, Spain.

Physiotherapy has emerged as a promising approach for managing this condition. In Sweden, patients receiving physiotherapy as a first-line treatment generated lower total healthcare costs. Similarly, in the United States, musculoskeletal patients who initiated care with physiotherapy achieved better cost-effectiveness, required fewer sessions, and experienced greater functional recovery.

Diagnosing shoulder pain accurately remains challenging for clinicians, primarily due to inconsistencies and a lack of uniformity in diagnostic nomenclature and criteria. Consequently, diagnosis may need to rely on sub-classifications of patients with reliably reproducible characteristics. In this context, rotator cuff-related shoulder pain is consistently reported as the most prevalent diagnosis in individuals with shoulder pain.

Patients with rotator cuff-related shoulder pain often report moderate-to-severe pain intensity, limitations in daily activities, reduced range of motion, and/or loss of strength. Persistent pain in this condition is also commonly associated with psychosocial factors, such as fear of movement, pain hypervigilance, and/or loss of self-efficacy-barriers that can hinder recovery. Collectively, these factors significantly affect patients' quality of life.

A novel aspect of this project is the proposed examination of biomarkers associated with systemic inflammation and chronic pain in this clinical population, specifically C-reactive protein (CRP) and calcitonin gene-related peptide (CGRP). C-reactive protein is a marker of systemic inflammation, with elevated levels linked to various chronic pain conditions, suggesting an inflammatory component that may modulate pain perception and intensity in these patients. Meanwhile, CGRP is a neuropeptide involved in nociceptive signal transmission and inflammatory response modulation. Elevated CGRP levels have been documented in several chronic pain conditions, including osteoarthritis, migraines, and joint disorders, where peripheral and central sensitization processes are present.

In animal studies, CGRP has been shown to play a role in triggering neurogenic inflammation and its association with pain pathways. In conditions like rotator cuff-related shoulder pain, characterized by persistent pain, complex interactions between inflammatory processes and neurobiological mechanisms are likely to occur. Evaluating these biomarkers is particularly relevant to deepen our understanding of the underlying pathophysiological mechanisms in this patient population.

The use of virtual reality (VR) has emerged as an innovative strategy for managing patients with pain, disability, and reduced quality of life. On one hand, it can modulate the context of motor relearning, an aspect of particular relevance for individuals with persistent shoulder pain, where strength and mobility deficits are common. On the other hand, the hypoalgesic mechanisms underlying the effects of VR are multifactorial, mediated by various dimensions of the pain experience, including sensory-discriminative, affective-motivational, and evaluative-cognitive aspects, as well as motor behavior itself.

Moreover, VR appears to modulate pain perception by stimulating auditory, visual, and sensorimotor neural networks and activating descending inhibitory systems, thereby influencing pain perception. Interestingly, severe pain and disability, rather than being contraindications, may serve as indications for implementing VR.

This therapeutic approach can also be tailored to the individual needs of patients, considering factors such as functional levels, social context, and age, which may influence adaptability to the technology and, consequently, treatment adherence and outcomes.

Finally, VR has demonstrated its potential as a high-quality, cost-effective treatment option for chronic low back pain, highlighting its capacity to provide an accessible and effective alternative that reduces the economic burden on healthcare systems and patients alike.

Conditions
Shoulder Pain
Being tested
Immersive Virtual Reality, Exercise
Keywords
shoulder pain, virtual reality, exercise, randomized clinical trial, chronic pain
Medical subject headings
Shoulder Pain, Motor Activity, Chronic Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Immersive Virtual RealityDevice

    Also called virtual reality

    Participants in the experimental group will follow a treatment program that combines standard care with an immersive virtual reality (IVR) intervention. During the first 4 weeks, participants will undergo the IVR intervention, followed by the same standard treatment as the control group for the subsequent 8 weeks.

    IVR Intervention Protocol:

    Sessions and Equipment: Participants will attend up to 12 IVR sessions using a head-mounted device (HMD), the Meta Quest III, equipped with a hand-tracking system (Meta VR, Facebook, California) to enable interaction with the therapeutic software Dynamics PainRehab (Dynamics VR Rehab, Seville, Spain). The Meta Quest III HMD is chosen for its commercial availability, widespread use, minimal visual latency, and user-friendly interface. The software application, "Hombro PainRehab," features multisensory inputs (vision and sound), high-quality graphics, head and hand tracking, and provides a highly immersive experience. The IVR intervention incorporate

  • ExerciseProcedure or surgery

    Participants assigned to the control group will receive standard treatment for rotator cuff-related shoulder pain. This will consist of standardized therapeutic exercise performed for 25 minutes, 3 times per week, over a 12-week period. The exercise regimen will be individualized based on intensity, utilizing the Rate of Perceived Exertion (RPE) scale, with the goal of achieving intensity levels of 6-8 on a scale of 0 to 10.

Study groups in NCT06795464
Study groupRoleWhat they receive
Control groupActive comparatorParticipants assigned to the control group will receive standard treatment for rotator cuff-related shoulder pain. This will consist of standardized therapeutic exercise performed for 25 minutes, 3 times per week, over a 12-week period. The exercise regimen will be individualized based on intensity, utilizing the Rate of Perceived Exertion (RPE) scale, with the goal of achieving intensity levels of 6-8 on a scale of 0 to 10
Receives: Procedure: Exercise
Experimental groupExperimentalParticipants in the experimental group will follow a treatment program that combines standard care with an immersive virtual reality (IVR) intervention. During the first 4 weeks, participants will undergo the IVR intervention, followed by the same standard treatment as the control group for the subsequent 8 weeks. IVR Intervention Protocol: Sessions and Equipment: Participants will attend up to 12 IVR sessions using a head-mounted device (HMD), the Meta Quest III, equipped with a hand-tracking system (Meta VR, Facebook, California) to enable interaction with the therapeutic software Dynamics PainRehab (Dynamics VR Rehab, Seville, Spain). The Meta Quest III HMD is chosen for its commercial availability, widespread use, minimal visual latency, and user-friendly interface. The software application, "Hombro PainRehab," features multisensory inputs (vision and sound), high-quality graphics, head and hand tracking, and provides a highly immersive experience. The IVR intervention incorporat
Receives: Device: Immersive Virtual Reality; Procedure: Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Intensity

    Pain intensity will be assessed using the Numeric Pain Rating Scale (NPRS), a visual 11-point scale ranging from 0 (no pain) to 10 (worst imaginable pain).

    Measured: Baseline, 1, 2 and 3 months follow-up

  2. Shoulder disability

    Self-reported shoulder function will be evaluated using the Spanish version of the Shoulder Pain And Disability Index (SPADI). This questionnaire, originally developed to assess shoulder pain and disability through 13 items (Williams et al., 1995), has been described as a tool capable of effectively discriminating between patients with improving or worsening conditions (Roy et al., 2009). Following a transcultural adaptation, the Spanish version (Membrilla-Mesa et al., 2015) retains the 13 items, assessing pain and disability in shoulder dysfunction. This patient-reported outcome measure is suitable for both clinical practice and research.

    Measured: Baseline, 1, 2 and 3 months follow-up

  3. Shoulder external rotation strength

    Isometric shoulder strength in external rotation will be measured using a MicroFET 2 MT Digital Handheld Dynamometer (Hoggan Health Industries, West Draper, UT). Handheld dynamometry has demonstrated good-to-excellent intra-examiner reliability for measuring isometric shoulder strength (Intraclass Correlation Coefficient = 0.87-0.99) (McLaine et al., 2016; Holt et al., 2016).

    Measured: Baseline, 1, 2 and 3 months follow-up

  4. Handgrip strength

    Handgrip strength will be assessed using a Jamar Hand Dynamometer (Sammons Preston Rolyan, Bolingbrook, IL). This device has shown good-to-excellent intra-examiner reliability for measuring isometric handgrip strength (Intraclass Correlation Coefficient = 0.85-0.98) (Roberts et al., 2011).

    Measured: Baseline, 1, 2 and 3 months follow-up

  5. Shoulder mobility

    Shoulder mobility will be assessed during movements of flexion, abduction, external rotation at 0° abduction, external rotation at 90° abduction, and internal rotation at 90° abduction. Measurements will be conducted using a smartphone application-based inclinometer (Plaincode Software Solutions, Gunzenhausen, Germany), which has been validated with excellent inter-examiner reliability and validity in symptomatic individuals (Intraclass Correlation Coefficient > 0.80) (Werner et al., 2014).

    Measured: Baseline, 1, 2 and 3 months follow-up

Secondary outcomes (9)
  1. Biomarkers

    A blood sample will be collected from the antecubital vein, which will subsequently undergo centrifugation, aliquoting, and storage at -80°C until analysis. This procedure will be conducted in the Exercise Physiology Research Laboratory of UFV by nurses from the external laboratory Eurofins Megalab, who will be responsible for the collection and analysis of biological samples.

    The blood markers to be evaluated in the participants include:

    Oxidative stress and inflammation biomarkers: C-reactive protein (CRP). Neurobiological markers associated with chronic pain processes: calcitonin gene-related peptide (CGRP).

    Measured: Baseline, 1 and 3 months follow-up

  2. Self-reported quality of life

    Quality of life will be assessed using the SF-12 (Short Form Health Survey), which evaluates eight health dimensions related to perceived quality of life. The SF-12 has been shown to be a reliable and valid instrument in diverse populations (Ware et al., 1996).

    Measured: Baseline, 1, 2 and 3 months follow-up

  3. Kinesiophobia

    Fear of movement will be measured using the Tampa Scale for Kinesiophobia (TSK). This scale evaluates fear of movement and has demonstrated high reliability and internal consistency (Intraclass Correlation Coefficient = 0.76-0.90) (Vlaeyen et al., 1995).

    Measured: Baseline, 1, 2 and 3 months follow-up

  4. Daily Activity Avoidance Behaviors

    Daily activity avoidance behaviors will be assessed with the Shoulder Activity Daily Avoidance Photographic Scale (Shoulder ADAP Scale) (Ansanello et al., 2022). This scale includes 15 photographs distributed across three domains, assessing pain-related activity avoidance in individuals with unilateral or bilateral shoulder pain. Scores range from 0 to 100 (0 = no avoidance, 100 = extreme avoidance), with 15 items distributed as follows:

    Free Movement (5 items): Total = [(sum × 10)/5] High Effort (7 items): Total = [(sum × 10)/7] Self-Care (3 items): Total = [(sum × 10)/3] The total score is calculated as Total = [(sum × 10)/15]. The Shoulder ADAP Scale has shown internal consistency values of 0.92 for free movement (factor 1), 0.89 for high effort (factor 2), and 0.92 for self-care (factor 3), with excellent test-retest reliability (ICC = 0.94) across all domains and the total score (Ansanello et al., 2023; Scaglione et al., 2024).

    Measured: Baseline, 1, 2 and 3 months follow-up

  5. Pain hypervigilance

    Pain hypervigilance will be assessed using the Pain Vigilance and Awareness Questionnaire (PVAQ), a tool designed to measure attention and vigilance to pain. The PVAQ has demonstrated high internal reliability and validity in various clinical contexts (McCracken, 1997).

    Measured: Baseline, 1, 2 and 3 months follow-up

  6. Self efficacy

    Self-efficacy will be measured using the Pain Self-Efficacy Questionnaire (PSEQ), which evaluates patients' confidence in their ability to perform activities despite pain. The PSEQ has shown excellent reliability and validity in populations with chronic pain (Nicholas, 2007).

    Measured: Baseline, 1, 2 and 3 months follow-up

  7. Motor and functional deficits related to pain

    Motor and functional deficits related to pain will be assessed using the 16-item version of the Biobehavioral Pain and Movement Questionnaire (CBioD-MOV). This tool evaluates four major subscales: physical activity self-efficacy, disability, movement avoidance behavior, and perceived functional capacity. The CBioD-MOV uses a 5-point Likert scale and scores range from 0 to 62. The psychometric adaptation of the Spanish version has shown good-to-excellent reliability for Standard Error of Measurement (SEM) and Minimal Detectable Change (MDC) (La Touche et al., 2024).

    Measured: Baseline, 1, 2 and 3 months follow-up

  8. Implicit motor imagery performance

    Implicit motor imagery performance will be evaluated using a left/right judgment task. Participants will view a series of shoulder images displayed on a computer screen and determine whether the images depict a left or right shoulder. This test has shown adequate reliability (Breckenridge et al., 2017). The task will be performed using the Recognise™ software (noigroup.com, Adelaide, Australia), where participants will complete a block of 30 randomized images of shoulders in various postures and rotations. Participants must identify the correct side as quickly and accurately as possible by pressing the corresponding key on the screen.

    Measured: Baseline, 1, 2 and 3 months follow-up

  9. Sleep quality

    Sleep quality will be estimated using the Oviedo Sleep Questionnaire (COS), designed to assess sleep disorders, particularly insomnia and hypersomnia. The COS consists of 15 items, 13 of which are grouped into three subscales:

    Subjective Sleep Satisfaction: Item 1 (scored 1-7). Insomnia: Items 2-1, 2-2, 2-3, 2-4, 3, 4, 5, 6, 7 (scored 1-5; total range: 9-45).

    Hypersomnia: Items 2-5, 8, 9 (scored 1-5). Two additional items provide information on the use of sleep aids and adverse sleep events. Higher scores in the insomnia subscale indicate greater severity. The COS has demonstrated adequate concurrent validity and reliability (Bobes et al., 1998).

    Measured: Baseline, 1, 2 and 3 months follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2025
  2. Study start1 Mar 2025
  3. Primary completion28 Apr 2026
  4. Study completion28 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
44 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06795464
Sponsor's protocol ID
SHOULDERVIRTUALREALITY
Other IDs
UFV-2025/
Acronym
SHOULDERVR
Status last verified
Jan 2025
First submitted
21 Jan 2025
Last updated
4 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: At this time, there are no plans to share individual participant data (IPD). The primary reason for this decision is to protect the confidentiality and privacy of participants, as sharing IPD may pose a risk of re-identification despite anonymization efforts. Additionally, the study does not have a specific framework or infrastructure in place for secure and compliant IPD sharing. However, summary data and results of the study will be disseminated through peer-reviewed publications and presentations at scientific conferences, ensuring that the scientific community and the public can benefit from the findings.

Publications

  • Ahmadpour N, Randall H, Choksi H, Gao A, Vaughan C, Poronnik P. Virtual Reality interventions for acute and chronic pain management. Int J Biochem Cell Biol. 2019 Sep;114:105568. doi: 10.1016/j.biocel.2019.105568. Epub 2019 Jul 12.

    PubMed 31306747

Questions about this trial

What is this clinical trial studying?

A study testing Immersive Virtual Reality and Exercise in people with Shoulder Pain, run by Universidad Francisco de Vitoria at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Intensity (time frame: Baseline, 1, 2 and 3 months follow-up). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06795464, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in